Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
Predictably Tacti-003 fails, but funding is secured – from investors, not a partner.
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
The ROR1 data are sketchy, and lung toxicity clouds prospects.